Preprint · CC-BY
via OpenAlex
Tissue-Restricted Inhibition of mTOR Using Chemical Genetics
Douglas R. Wassarman, Kondalarao Bankapalli, Leo J. Pallanck, Kevan M. Shokat
bioRxiv (Cold Spring Harbor Laboratory) · 2022 · ▲ 1 citations
Deregulated nutrient-sensing
Altered intercellular communication
Rapamycin / mTOR inhibition
Yeast
Human
Drosophila
Abstract
Abstract mTOR(definition) is a highly conserved eukaryotic protein kinase that coordinates cell growth and metabolism and plays a critical role in cancer, immunity, and aging. It remains unclear how mTOR signaling in individual tissues contributes to whole-organism processes because mTOR inhibitors, like the natural product Rapamycin(definition), are administered systemically and target multiple tissues simultaneously. We developed a chemical-genetic system, termed selecTOR, that restricts the activity of a Rapamycin analog to specific cell populations through targeted expression of a mutant FKBP12 protein. This analog has reduced affinity for its obligate binding partner FKBP12, which reduces its ability to inhibit mTOR in wild-type cells and tissues. Expression of the mutant FKBP12, which contains an expanded binding pocket, rescues the activity of this Rapamycin analog. Using this system, we show that selective mTOR inhibition can be achieved in S. cerevisiae and human cells, and we validate the utility of our system in an intact metazoan model organism by identifying the tissues responsible for a Rapamycin-induced developmental delay in Drosophila . Significance Statement mTOR plays a number of critical organismal roles, including in cell growth, development, immunity and aging, but dissecting the tissue-specific influences of mTOR has proven challenging. This work describes a simple system for identifying the specific tissues and cells responsible for the diverse functions of mTOR, and we show that our system can be used in organisms ranging from yeast to humans.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1101/2022.03.08.483534
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Wassarman, D.R., Bankapalli, K., Pallanck, L.J., & Shokat, K.M. (2022). Tissue-Restricted Inhibition of mTOR Using Chemical Genetics. <em>bioRxiv (Cold Spring Harbor Laboratory)</em>. https://doi.org/10.1101/2022.03.08.483534
Vancouver
Wassarman DR, Bankapalli K, Pallanck LJ, Shokat KM. Tissue-Restricted Inhibition of mTOR Using Chemical Genetics. bioRxiv (Cold Spring Harbor Laboratory). 2022. doi:10.1101/2022.03.08.483534.
BibTeX
@unpublished{douglas2022Tissue,
title = {Tissue-Restricted Inhibition of mTOR Using Chemical Genetics},
author = {Douglas R. Wassarman and Kondalarao Bankapalli and Leo J. Pallanck and Kevan M. Shokat},
journal = {bioRxiv (Cold Spring Harbor Laboratory)},
year = {2022},
doi = {10.1101/2022.03.08.483534},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Research and Reports in Biology 2015
Open access · CC-BY
Recent insights into the pathophysiology of mTOR pathway dysregulation
Cancer Biology & Therapy 2013
Open access · OA
Dysregulation of the mTOR pathway in p53-deficient mice
European Journal of Immunology 2021
Open access · CC-BY
mTOR‐dependent immunometabolism as Achilles' heel of anticancer therapy
Cell Death and Disease 2024
Open access · CC-BY
The regulations of telomerase reverse transcriptase (TERT) in cancer
Biochemical Society Transactions 2013
Citation only
Adaptation to chronic mTOR inhibition in cancer and in aging
Genetics 2011
Open access · OA